Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1992 Jul;141(1):203–209.

Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice.

S Frizelle 1, J Schwarz 1, S A Huber 1, K Leslie 1
PMCID: PMC1886579  PMID: 1321562

Abstract

Coxsackievirus, Group B, type 3 (CVB3) infection of A/J male mice induces chronic myocarditis with increased interstitial fibrosis and collagen deposition. Heparin, a naturally occurring sulfated glycosaminoglycan, has both anti-inflammatory and antifibrotic activities besides its well-known anticoagulant activity. This study determined whether heparin treatment could decrease either cardiac inflammation or fibrosis in chronic CVB3-induced myocarditis. Control mice were either untreated or treated with heparin (4 micrograms/g body weight, subcutaneously 5 times weekly) beginning 2 days before infection of other groups. Additional groups received either virus only (1 x 10(4) plaque-forming units [PFU]), virus followed by heparin beginning 14 days after CVB3 inoculation, or virus and heparin beginning 2 days before CVB3 inoculation. Animals were sacrificed 14, 28, and 58 days after infection. Heparin treatment begun either before or after virus inoculation reduced animal mortality by approximately 20%. Heparin did not alter virus infection or replication in the heart. Histologically, only animals treated with heparin before virus inoculation showed reduced myocardial inflammation, and only at day 58. However, heparin treatment begun either before or after virus infection significantly decreased collagen deposition in the heart (fibrosis).

Full text

PDF
203

Images in this article

207Figure 4
on p.207

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelmann W. H., Adesanya C. O., Goldberg A. H., Phear W. P., Young N. A. Depressed myocardial function in subacute experimental viral myocarditis. Recent Adv Stud Cardiac Struct Metab. 1975;6:535–542. [PubMed] [Google Scholar]
  2. Abelmann W. H. Viral myocarditis and its sequelae. Annu Rev Med. 1973;24:145–152. doi: 10.1146/annurev.me.24.020173.001045. [DOI] [PubMed] [Google Scholar]
  3. Asselot C., Labat-Robert J., Kern P. Heparin fragments regulate collagen phenotype and fibronectin synthesis in the skin of genetically diabetic mice. Biochem Pharmacol. 1989 Mar 15;38(6):895–899. doi: 10.1016/0006-2952(89)90277-3. [DOI] [PubMed] [Google Scholar]
  4. Baba M., Snoeck R., Pauwels R., de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988 Nov;32(11):1742–1745. doi: 10.1128/aac.32.11.1742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benecky M. J., Kolvenbach C. G., Amrani D. L., Mosesson M. W. Evidence that binding to the carboxyl-terminal heparin-binding domain (Hep II) dominates the interaction between plasma fibronectin and heparin. Biochemistry. 1988 Sep 20;27(19):7565–7571. doi: 10.1021/bi00419a058. [DOI] [PubMed] [Google Scholar]
  6. Bratt G., Törnebohm E., Lockner D., Bergström K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost. 1985 Apr 22;53(2):208–211. [PubMed] [Google Scholar]
  7. CRAIGHEAD J. E. SOME PROPERTIES OF THE ENCEPHALOMYOCARDITIS, COLUMBIA SK AND MENGO VIRUSES. Proc Soc Exp Biol Med. 1965 Jun;119:408–412. doi: 10.3181/00379727-119-30196. [DOI] [PubMed] [Google Scholar]
  8. Castor C. W., Miller J. W., Walz D. A. Structural and biological characteristics of connective tissue activating peptide (CTAP-III), a major human platelet-derived growth factor. Proc Natl Acad Sci U S A. 1983 Feb;80(3):765–769. doi: 10.1073/pnas.80.3.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. DOUGHERTY T. F., HIGGINBOTHAM R. D. Mechanism of heparin protection against a histamine releasor. Proc Soc Exp Biol Med. 1956 Jul;92(3):493–498. doi: 10.3181/00379727-92-22522. [DOI] [PubMed] [Google Scholar]
  10. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol. 1989 Jul 1;143(1):356–365. [PubMed] [Google Scholar]
  11. Dziarski R. Enhancement of mixed leukocyte reaction and cytotoxic antitumor responses by heparin. J Immunol. 1989 Jul 1;143(1):356–365. [PubMed] [Google Scholar]
  12. Fantuz M., Bertoli D. General pharmacological properties of a low molecular weight heparin in rodents. Arzneimittelforschung. 1986 Sep;36(9):1366–1368. [PubMed] [Google Scholar]
  13. Hanahoe T. H., Jones D. R. Heparin and acute inflammation in the rat. Int Arch Allergy Appl Immunol. 1988;86(2):243–244. doi: 10.1159/000234579. [DOI] [PubMed] [Google Scholar]
  14. Huber S. A., Lodge P. A. Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am J Pathol. 1984 Jul;116(1):21–29. [PMC free article] [PubMed] [Google Scholar]
  15. Lerner A. M., Wilson F. M. Virus myocardiopathy. Prog Med Virol. 1973;15:63–91. [PubMed] [Google Scholar]
  16. Leslie K. O., Schwarz J., Simpson K., Huber S. A. Progressive interstitial collagen deposition in Coxsackievirus B3-induced murine myocarditis. Am J Pathol. 1990 Mar;136(3):683–693. [PMC free article] [PubMed] [Google Scholar]
  17. Lodge P. A., Herzum M., Olszewski J., Huber S. A. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 1987 Sep;128(3):455–463. [PMC free article] [PubMed] [Google Scholar]
  18. McPherson J. M., Ledger P. W., Ksander G., Sawamura S. J., Conti A., Kincaid S., Michaeli D., Clark R. A. The influence of heparin on the wound healing response to collagen implants in vivo. Coll Relat Res. 1988 Jan;8(1):83–100. doi: 10.1016/s0174-173x(88)80037-2. [DOI] [PubMed] [Google Scholar]
  19. Murray T. G., Stern W. H., Chin D. H., MacGowan-Smith E. A. Collagen shield heparin delivery for prevention of postoperative fibrin. Arch Ophthalmol. 1990 Jan;108(1):104–106. doi: 10.1001/archopht.1990.01070030110039. [DOI] [PubMed] [Google Scholar]
  20. Salzman E. W. Low-molecular-weight heparin: is small beautiful? N Engl J Med. 1986 Oct 9;315(15):957–959. doi: 10.1056/NEJM198610093151509. [DOI] [PubMed] [Google Scholar]
  21. Sy M. S., Schneeberger E., McCluskey R., Greene M. I., Rosenberg R. D., Benacerraf B. Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity. Cell Immunol. 1983 Nov;82(1):23–32. doi: 10.1016/0008-8749(83)90137-5. [DOI] [PubMed] [Google Scholar]
  22. WOESSNER J. F., Jr The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys. 1961 May;93:440–447. doi: 10.1016/0003-9861(61)90291-0. [DOI] [PubMed] [Google Scholar]
  23. Wiseman E. H., Chang Y. H. The role of fibrin in the inflammatory response to carrageenin. J Pharmacol Exp Ther. 1968 Jan;159(1):206–210. [PubMed] [Google Scholar]
  24. Wolfgram L. J., Beisel K. W., Herskowitz A., Rose N. R. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol. 1986 Mar 1;136(5):1846–1852. [PubMed] [Google Scholar]
  25. Woodruff J. F., Kilbourne E. D. The influence of quantitated post-weaning undernutrition on coxsackievirus B3 infection of adult mice. I. Viral persistence and increased severity of lesions. J Infect Dis. 1970 Feb;121(2):137–163. doi: 10.1093/infdis/121.2.137. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES